Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR1A | P08908 | 2/20 | 0.49 |
| ▸ | DRD2 | P14416 | 2/20 | 0.49 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | ABCB1 | P08183 | 6/20 | 0.45 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.45 |
| ▸ | TRPV6 | Q9H1D0 | 1/20 | 0.43 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.42 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | PKM | P14618 | 1/20 | 0.42 |
| ▸ | MGLL | Q99685 | 1/20 | 0.41 |
| ▸ | BCHE | P06276 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19988039 | 0.83 | HTR1A (0.46) | HTR1ADRD2L3MBTL1LMNAABCB1 | |
| SCHEMBL18894534 | 0.81 | HTR1A (0.53) | HTR1ADRD2L3MBTL1LMNAABCB1 | |
| SCHEMBL28020148 | 0.81 | HTR1A (0.53) | HTR1ADRD2L3MBTL1LMNAABCB1 | |
| SCHEMBL16797594 | 0.81 | HTR1A (0.53) | HTR1ADRD2L3MBTL1LMNAABCB1 | |
| SCHEMBL20179434 | 0.81 | HTR1A (0.43) | HTR1ADRD2L3MBTL1LMNAABCB1 | |
| SCHEMBL20175295 | 0.81 | HTR1A (0.43) | HTR1ADRD2L3MBTL1LMNAABCB1 | |
| SCHEMBL6216693 | 0.78 | HTR1A (0.51) | HTR1ADRD2L3MBTL1LMNAABCB1 | |
| SCHEMBL6216285 | 0.78 | ELANE (0.53) | HTR1ADRD2L3MBTL1LMNAABCB1 | |
| SCHEMBL15583063 | 0.78 | HTR1A (0.51) | HTR1ADRD2L3MBTL1LMNAABCB1 | |
| SCHEMBL7450663 | 0.78 | HTR1A (0.51) | HTR1ADRD2L3MBTL1LMNAABCB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3974419-A2 | NEBIVOLOL SYNTHESIS METHOD AND INTERMEDIATE COMPOUND THEREOF | Zhejiang Ausun Pharmaceutical Co., Ltd. (CN) | 2022-03-30 | — | — | EP | disclosed |
| US-20220056003-A1 | NEBIVOLOL SYNTHESIS METHOD AND INTERMEDIATE COMPOUND THEREOF | ZHEJIANG AUSUN PHARMACEUTICAL CO., LTD. (CN) | 2022-02-24 | — | — | US | disclosed |
| US-11142512-B2 | Nebivolol synthesis method and intermediate compound thereof | ZHEJIANG AUSUN PHARMACEUTICAL CO., LTD. (CN) | 2021-10-12 | — | — | US | disclosed |
| US-20200102282-A1 | NEBIVOLOL SYNTHESIS METHOD AND INTERMEDIATE COMPOUND THEREOF | ZHEJIANG AUSUN PHARMACEUTICAL CO., LTD. (CN) | 2020-04-02 | — | — | US | disclosed |
| US-20180141926-A1 | NEBIVOLOL SYNTHESIS METHOD AND INTERMEDIATE COMPOUND THEREOF | ZHEJIANG AUSUN PHARMACEUTICAL CO., LTD. (CN) | 2018-05-24 | — | — | US | disclosed |
| US-20180141926-A1 | NEBIVOLOL SYNTHESIS METHOD AND INTERMEDIATE COMPOUND THEREOF | ZHEJIANG AUSUN PHARMACEUTICAL CO., LTD. (CN) | 2018-05-24 | — | — | US | disclosed |
| EP-3299364-A1 | NEBIVOLOL SYNTHESIS METHOD AND INTERMEDIATE COMPOUND THEREOF | Zhejiang Ausun Pharmaceutical Co., Ltd. (CN) | 2018-03-28 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200102282-A1 | NEBIVOLOL SYNTHESIS METHOD AND INTERMEDIATE COMPOUND THEREOF | CYP4A11, CYP11B2, ADRB1 | HTR1A 1318/4885DRD2 205/4885L3MBTL1 3400/4885 |
| US-11142512-B2 | Nebivolol synthesis method and intermediate compound thereof | CYP4A11, CYP11B2, ADRB1 | HTR1A 1318/4885DRD2 205/4885L3MBTL1 3400/4885 |
| US-20220056003-A1 | NEBIVOLOL SYNTHESIS METHOD AND INTERMEDIATE COMPOUND THEREOF | CYP4A11, CYP11B2, CYP11B1 | HTR1A 1267/4885DRD2 222/4885L3MBTL1 3660/4885 |
| US-20180141926-A1 | NEBIVOLOL SYNTHESIS METHOD AND INTERMEDIATE COMPOUND THEREOF | CYP4A11, CYP11B2, ADRB1 | HTR1A 1318/4885DRD2 205/4885L3MBTL1 3400/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.